ReviewInternational journal of clinical oncology2016
Basics of PD-1 in self-tolerance, infection, and cancer immunity.
Review in International journal of clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 85 citations in OpenAlex.
- PD-1Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Signaling Under Stress: Targeting the Glucocorticoid Receptor in Cancer.Cancer research · 2026Review
- Molecular origin, discovery, validation and application of neoantigens.Asian journal of pharmaceutical sciences · 2026Review
- The role of PD-1 and Tim-3 in regulating the suppressive activity of myeloid-derived suppressor cells in axial spondyloarthritis: association with clinical and laboratory parameters.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Heme oxygenase-1 emerges as a critical regulator linking autophagy dysregulation, immune infiltration, and NOD-Like receptor signaling in PCOS pathogenesis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Role of PD-L1 in the Pathogenesis of Pre-Eclampsia and Its Association with Adverse Fetal Outcomes.Turk patoloji dergisi · 2026Article
- Impact of immune checkpoint inhibitors on pregnancy: current evidence and future directions.BMJ oncology · 2026Review
- Circulating stem-like exhausted CD8 T cells point to better outcomes in lung cancer: a brief report.Translational lung cancer research · 2025Article
- Blocking the IL‑6 pathway to treat immune checkpoint inhibitor‑induced inflammatory arthritis (Review).Molecular medicine reports · 2025Review
- Mechanisms of immune suppression in sepsis/shock: one investigator's/lab group's experience (SLB 2024 legacy award presentation).Journal of leukocyte biology · 2025Article
- Development of machine learning models for diagnostic biomarker identification and immune cell infiltration analysis in PCOS.Journal of ovarian research · 2025Article
- Regulatory mechanisms of PD-1/PD-L1 in cancers.Molecular cancer · 2024Review
- Balancing the Nanoscale Organization in Multivalent Materials for Functional Inhibition of the Programmed Death-1 Immune Checkpoint.ACS nano · 2024Article
- A case report of the diagnosis and treatment of immune checkpoint inhibitor-related encephalitis induced by camrelizumab.AME case reports · 2024Article
- Expression of PD-1 and PD-L1 in Endometrial Cancer: Molecular and Clinical Significance.International journal of molecular sciences · 2023Review
- Sintilimab treatment for chronic active Epstein-Barr virus infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children.Orphanet journal of rare diseases · 2023Article
- The role of PD-1 signaling in health and immune-related diseases.Frontiers in immunology · 2023Review
- Article
- Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs.The Journal of clinical investigation · 2022Article
- SPOP promotes cervical cancer progression by inducing the movement of PD-1 away from PD-L1 in spatial localization.Journal of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Successful cancer treatment requires understanding host immune response against tumor cells. PD-1 belongs to the CD28 superfamily of receptors that work as "checkpoints" of immune activation. PD-1 maintains immune self-tolerance to prevent autoimmunity and controls T-cell reaction during infection to prevent excessive tissue damage. Tumor cells that arise from normal tissue acquire mutations that can be targeted by lymphocytes. Accumulating lines of evidence suggest that tumor cells evade host immune attack by expressing physiological PD-1 ligands and stimulating PD-1 on the lymphocytes. Based on this idea, researchers have successfully demonstrated that systemic administration of monoclonal antibodies that inhibit the binding of PD-1 to the ligands reactivated T cells and augmented the anti-cancer immune response. In this review, I summarize the basics of T-cell biology and its regulation by PD-1 and discuss the current understanding and questions about this multifaceted molecule.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.